

Demographics and basic clinical information	Date of birth* Sex* Country of origin* Ethnicity* Date first seen at department* Date of most recent clinic visit Date of first positive HIV1-Ab test* If known, date of last negative HIV-1 Ab test* Mode of HIV-infection* Mode of HCV-infection† Body weight Height* Blood pressure Smoking status Alcohol abuse** Injection drug use** Pregnancy and mother to child transmission‡
Laboratory values	HIV-RNA CD4 cell count CD8 cell count§ Haemoglobin** Serum creatinine Platelets ALT (alanine transaminase) AST (aspartate transaminase) Albumin Bilirubin INR** Total cholesterol HDL cholesterol LDL cholesterol Serum triglycerides HbA1c Plasma glucose Urine dipstick HBsAg (hepatitis B virus s-antigen) HBV-DNA, anti-HBs (hepatitis B surface antibody), HBe-IgG (hepatitis B core antibody), IgM + IgG anti-HBc (hepatitis B core antibody total)‡ Anti-HCV IgG (anti-hepatitis C virus antibodies) HCV-RNA HCV genotype and subtype Parathyroid hormone‡ Prostate specific antigen‡
Other tests	Resistance test Plasma samples

	<p>HLA B*5701§</p> <p>Bone mass density§</p> <p>Fibroscan†</p> <p>Liver biopsy</p> <p>CT and/or Ultrasound of abdomen/liver performed?†</p>
Antiretroviral therapy	<p>Start- and stop-dates</p> <p>Reason for discontinuation</p> <p>Adherence to antiretroviral therapy‡</p> <p>Hypersensitivity reactions and liver toxicity to integrase inhibitors‡</p>
Treatment related to risk of cardiovascular disease	<p>Start- and stop-dates of antihypertensives, ACE-inhibitors, insulin or derivatives hereof, oral antidiabetic agents, antiplatelets, statins, fibrates, lipid lowering agents (not further specified)</p>
Treatment of hepatitis C	<p>Start- and stop-date†</p> <p>Start- and stop dosage†</p> <p>Discontinuation of anti-HCV treatment before scheduled, and reason for discontinuation†</p> <p>Adherence to anti-HCV treatment†</p> <p>Adverse events to anti-HCV treatment and outcome of adverse event†</p>
Other medical treatment	<p>Opiate substitution therapy†</p> <p>Antipsychotic therapy‡</p> <p>Antidepressant drugs‡</p> <p>Benzodiazepines‡</p> <p>Vitamin D‡</p> <p>Bisphosphonates‡</p> <p>Treatment against infections (including primary prophylaxis)‡</p>
Clinical events and adverse events to antiretrovirals	<p>All AIDS-defining events (according to the CDC 1993 definition) [1]</p> <p>AIDS- and non-AIDS defining malignancies</p> <p>Cause of death</p> <p>Cardiovascular events (myocardial infarction (MI), invasive coronary procedure (ICP))</p> <p>Diabetes mellitus</p> <p>End stage renal disease (ESRD)</p> <p>End stage liver disease (ESLD)</p> <p>Fractures</p> <p>Avascular necrosis‡</p> <p>Pancreatitis‡</p> <p>Lipodystrophy‡</p>
Plasma samples	<p>Plasma samples collected twice annually from majority of clinics</p>
Selected specific surveys and laboratory measurements	<p>EuroSIDA clinic survey [45]</p> <p>Centrally tested prostate specific antigen [49]</p> <p>Survey of ATRIPLA use as first-line therapy [51]</p> <p>Centrally tested HCV RNA and HCV genotype [36,52]</p> <p>Centrally tested Vitamin D levels [53,54]</p> <p>Centrally tested hyaluronic acid [47,55]</p> <p>Centrally tested hepatitis delta [56]</p> <p>Centrally tested resistance [48]</p> <p>Survey of dialysis and renal transplantation [57]</p>

Table 2: Data available in EuroSIDA * collected only at enrolment into EuroSIDA. ** collected for all at enrolment into EuroSIDA, thereafter only for HIV/HCV-coinfected participants. † from dataset 44 (2016) and onward collected for HIV/HCV-coinfected participants only. ‡ not collected after dataset 44 (2016). § collected since dataset 45 (2017). ¶ collected since dataset 43 (2015). Numbers in brackets refer to references.